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BACKGROUND: Noninvasive genotyping of fetal RHD
(Rh blood group, D antigen) can prevent the unnecessary
administration of prophylactic anti-D to women carry-
ing RHD-negative fetuses. We evaluated laboratory
methods for such genotyping.
METHODS: Blood samples were collected in EDTA tubes
and Streck® Cell-Free DNA™ blood collection tubes
(Streck BCTs) from RHD-negative women (n  46).
Using Y-specific and RHD-specific targets, we investi-
gated variation in the cell-free fetal DNA (cffDNA) frac-
tion and determined the sensitivity achieved for optimal
and suboptimal samples with a novel Droplet Digital™
PCR (ddPCR) platform compared with real-time quan-
titative PCR (qPCR).
RESULTS: The cffDNA fraction was significantly larger for
samples collected in Streck BCTs compared with samples
collected inEDTAtubes (P0.001). In samples expressing
optimal cffDNA fractions (4%), both qPCR and digital
PCR (dPCR) showed 100% sensitivity for the TSPY1
(testis-specific protein, Y-linked 1) and RHD7 (RHD exon
7) assays. Although dPCR also had 100% sensitivity for
RHD5 (RHD exon 5), qPCRhad reduced sensitivity (83%)
for this target. For samples expressing suboptimal cffDNA
fractions (2%), dPCR achieved 100% sensitivity for all
assays, whereas qPCR achieved 100% sensitivity only for
the TSPY1 (multicopy target) assay.
CONCLUSIONS: qPCR was not found to be an effective
tool for RHD genotyping in suboptimal samples (2%
cffDNA). However, when testing the same suboptimal
samples on the same day by dPCR, 100% sensitivity was
achieved for both fetal sex determination and RHD geno-
typing. Use of dPCR for identification of fetal specific
markers can reduce the occurrence of false-negative and
inconclusive results, particularly when samples express
high levels of background maternal cell-free DNA.
© 2015 American Association for Clinical Chemistry
Diagnosis of fetal sex, RHD (Rh blood group, D anti-
gen)3 genotype, and chromosomal abnormalities can be
achieved only through analysis of fetal DNA. Initially,
this could be achieved through invasive procedures such
as amniocentesis and chorionic villus sampling, quoted as
having a 1% risk of miscarriage (1 ). Since the discovery
of cell-free fetal DNA (cffDNA)4 in maternal plasma,
noninvasive prenatal testing is now a clinical reality (1–
5 ). Fetal sex determination is offered in the clinic for
families at risk of X-linked disorders, such as Duchenne
muscular dystrophy (6 ). Determination of fetal sex is
especially beneficial in cases of congenital adrenal hyper-
plasia, to allow therapy to be targeted to female fetuses
only (7 ). Fetal aneuploidy detection requires accurate
quantification and presently can only be determined by
next-generation sequencing, which is too costly for rou-
tine testing (8 ).
The antigens of the Rh blood group system are
coded for by 2 genes, RHD and RHCE (Rh blood group,
CcEe antigens), which are located on chromosome 1
(p34–p36) (9 ). In white populations, most D-negative
phenotypes result from a complete RHD deletion (10 ).
For D-negative individuals of African descent, only 18%
are a result of RHD deletion. Instead, 66% and 15% of
D-negative Africans have an inactive RHD gene
(RHD) or a hybrid gene (RHD-CE-DS or r’S), which do
not produce any RhD protein (10, 11 ). Many laborato-
ries currently provide noninvasive fetal RHD genotyping
for alloimmunized women as routine practice to manage
hemolytic disease of the fetus and newborn (HDFN)
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(4, 12–14). Before 1970, HDFN was a major cause of
fetal mortality (46/100 000 births in the UK alone) (15 ),
but since the introduction of routine antenatal anti-D pro-
phylaxis, incidence has decreased nearly 10-fold (16). Cur-
rently, allRHD-negativewomen in theWest are offered this
prophylaxis, which is costly, as it is produced from hyper-
immunized male volunteers. Providing a noninvasive test
for fetal RHD genotyping allows administration to be tar-
geted to RHD-negative women who are known to be carry-
ing anRHD-positive fetus. This is now routine in theNeth-
erlands and Denmark with real-time quantitative PCR
(qPCR) approaches (4, 17, 18). However, recent publica-
tions have described the application of digital PCR (dPCR)
for the detection of low-level targets with improved preci-
sion, resulting in reliable quantification well below the limit
of quantification of qPCR (19, 20).
The use of Streck® Cell-Free DNA™ blood collec-
tion tubes (BCTs) instead of conventional EDTA tubes
has been shown to increase the proportion of cffDNA
(21 ). Streck BCTs contain proprietary cell-preserving re-
agents, which prevent maternal cell lysis and conse-
quently reduce the amount of maternal cell-free DNA
(cfDNA) released into the plasma. In this study, we com-
pared the sensitivity of dPCR and qPCR for the nonin-
vasive determination of fetal sex and RHD genotype for
samples collected in both Streck BCTs and EDTA tubes.
For technical reasons, some samples, despite being col-
lected in the third trimester, expressed suboptimal
cffDNA fractions (2%). However, all samples were in-
cluded to thoroughly test the capability of the dPCR
assay against the current gold standard, qPCR.
Materials and Methods
STUDY PARTICIPANTS
RHD-negative pregnant women (28–30 weeks’ gesta-
tion), all of whom met inclusion criteria, were recruited
at Plymouth Hospitals NHS Trust, Plymouth, UK, with
informed consent, from November 2013 to September
2014. Ethics approval was granted by the United Bristol
Healthcare and Trust Research and Ethics Committee
(13/SW/0148).
SAMPLE PROCESSING
Twenty-twomaternal peripheral blood samples were col-
lected in EDTA tubes (5–10mL total blood volume) and
centrifuged at 1600g for 10 min at room temperature
(samples 1–22). The plasma was carefully removed and
transferred to a 15-mL tube. The plasma was then recen-
trifuged at 16 000g for 10 min. All samples were pro-
cessed within 4 h of collection, and plasma aliquots (1
mL) were stored at 80 °C. RHD and RHD human
whole blood, collected in EDTA tubes (5 mL total blood
volume), was supplied by National Health Service Blood
and Transplant (Bristol, UK) as positive and negative
controls, respectively. These samples were processed
within 48–96 h by following the same double-spin pro-
tocol described above.
Twenty-four maternal blood samples collected in
Streck BCTs (10–20 mL total blood volume) were cen-
trifuged at 1600g for 15 min at room temperature (sam-
ples 23–46). Plasma was carefully removed, transferred
to a 50-mL tube, and recentrifuged at 2500g for 10 min.
All samples were processed within 48 h of collection, and
plasma aliquots (1 mL) were stored at80 °C.
DNA EXTRACTION
DNA was extracted from two 1-mL aliquots of plasma
with the QIAamp Circulating Nucleic Acid kit (Qiagen)
and QIAvac 24 Plus (Qiagen). The extraction process
followed the manufacturer’s protocol, and each sample
was eluted in 60 L Buffer AVE [RNase-free water con-
taining 0.04% (wt/vol) sodium azide]. No DNase or
RNase treatment was used. After DNA extraction, we
quantified samples on the Qubit® 2.0 Fluorometer (Life
Technologies) with the Qubit dsDNA HS assay kit (Life
Technologies). Samples were stored at20 °C as 60-L
aliquots for4 weeks.
PCR PRIMERS AND PROBES
For both dPCR and qPCR, we tested 4 multiplex reac-
tions: 2 for fetal sex determination and 2 for fetal RHD
genotyping (Table 1). Primer concentrations (300 to 900
nmol/L) and annealing temperatures (56 °C to 62 °C)
were optimized for all multiplex reactions. Fig. 1 shows
Table 1. Summary of amplicon location, length, and ﬂuorescent label for each multiplex reaction.
Multiplex
reaction Amplicon Chromosome Gene Exon/intron
Fluorescent
reporter dye Length, bp Origin
1 Target Y SRY Exon FAM 137 Lo et al. (22)
2 Target Y TSPY1 Exon FAM 88 In-house
1 and 2 Reference X Xp22.3 Intron HEX 95 Fan et al. (23)
3 Target 1 RHD5 Exon (5) FAM 82 Finning et al. (24)
4 Target 1 RHD7 Exon (7) FAM 75 Finning et al. (24)
3 and 4 Reference 1 AGO1 Exon HEX 81 Fan et al. (23)
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the optimization process for TSPY1-FAM/Xp22.3-
HEX.We used Xp22.3 oligonucleotides as a reference for
2 Y-specific targets [SRY (sex-determining region Y) (22 )
and TSPY1 (testis-specific protein, Y-linked 1)] for fetal
sex determination. AGO1 (argonaute RISC catalytic
component 1; formerly EIF2C1) primers were taken
from Fan et al. (23 ) and used as a reference for 2 RHD-
specific targets [RHD exon 5 (RHD5) and RHD exon 7
(RHD7)] (24 ) since AGO1 is also located on
chromosome 1. The oligonucleotide sequences (HPLC
purified, Eurofins Genomics) and amplicon sizes for all
target [carboxyfluorescein (FAM)-labeled] and reference
[hexachlorofluorescein (HEX)-labeled] regions are
shown in Supplemental File 1, which accompanies the
online version of this article at http://www.clinchem.org/
content/vol61/issue11. Sequences for the Xp22.3 reverse
primer and all TSPY1 oligonucleotides were designed
with online software (http://primer3.sourceforge.net and
http://www.idtdna.com/calc/analyzer) and subjected to
Basic Local Alignment Search Tool (BLAST) analysis
against the National Center for Biotechnology Informa-
tion GenBank DNA database (accession nos.
NC_000024.10 and NC_000023.11).
REAL-TIME qPCR
qPCR reactions were performed in a 20-L solution con-
taining 1 TaqMan Universal PCR Master Mix (Life
Technologies), 300 nmol/L primers, 250 nmol/L probes,
and a standard volume of template DNA (5 L). Sample
concentrations are recorded in online Supplemental File
2; because of the low abundance of cffDNA in extracted
maternal plasma, the samples were not diluted. Reactions
were conducted in duplicate, with positive and negative
controls for each assay. After optimization of annealing
temperature (Ta), cycling was carried out on a Life
Technologies StepOnePlus™ qPCR System under
the following conditions: 95 °C for 10 min, 50 cycles
of 95 °C for 15 s, and 58 °C for 1 min. Fifty cycles
were used to ensure amplification of low-copy-number
target DNA. We included a standard curve of male
genomic DNA (gDNA) (Promega) in triplicate on
each plate. We used FAM-labeled fluorescent probes
for all target regions (SRY, TSPY1, RHD5, and RHD7)
and HEX-labeled fluorescent probes for both refer-
ence regions (Xp22.3 and AGO1) (Table 1; also see
online Supplemental File 1).
Fig. 1. One-dimensional amplitude plot showing optimization of annealing temperature for TSPY1-FAM/Xp22.3-HEX multiplex
reaction.
(A), Separation of positive droplets (above threshold line) fromnegative droplets (below threshold line) for TSPY1-FAMampliﬁcation (Channel
1). The threshold for TSPY1 separation was manually set at 4000 amplitude. (B), Separation of positive droplets (above threshold line) from
negative droplets (below threshold line) for Xp22.3-FAM ampliﬁcation. The threshold for Xp22.3 separation was manually set at 2300
amplitude. Results illustrate optimal separation for both targets at 58 °C and 56 °C Ta.
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Digital PCR
dPCR reactions were performed in a 20-L solution con-
taining 10 L droplet digital PCR (ddPCR) Supermix
for Probes (Bio-Rad), 300 nmol/L primers, and 250
nmol/L probes. Because samples were not diluted after
Qubit quantification, we added a standard volume of
template DNA (5 L) with positive and negative con-
trols. All reactions were conducted in duplicate and run
on the QX100™ Droplet Generator (Bio-Rad) accord-
ing to the manufacturer’s instructions. By use of an oil
emersion approach, the sample was drawn through the
cartridge under a vacuum, where approximately 20 000
1-nL droplets were formed. The droplets (40 L total
volume) were then transferred to a 96-well plate and
covered with a pierceable foil heat seal on the PX1™
Plate Sealer (Bio-Rad). Cycling was carried out on a
C1000 Touch™ Thermal Cycler (Bio-Rad) under opti-
mized conditions: 95 °C for 10 min, 40 cycles of 95 °C
for 30 s, and 58 °C for 1 min, after which a final 98 °C
step for 10 min was carried out (as recommended by
Bio-Rad). Samples were analyzed immediately on the
QX100TM Droplet Reader (Bio-Rad). To ensure unifor-
mity, samples were extracted and tested by qPCR and
dPCR on the same day by the same investigator.
DATA ANALYSIS
For qPCR, targets with a mean quantification cycle (Cq)
of 45 were recorded as positive, provided no-template
controls (NTC) remained negative (Cq 45), to ensure
inclusion of low-copy-number targets. Targets that ex-
pressed Cq values45 for both duplicates were recorded
as negative. Thresholds were set at 0.05 for all targets
(StepOne™ Software v2.3).
We analyzed the raw fluorescent data from the
dPCR platform with Bio-Rad QuantaSoft v1.2 software.
Once thresholds for each sample had been set manually
with the 2-dimensional (2D) amplification plot, positive
and negative droplets were determined (Fig. 1; also see
online Supplemental File 3). Thresholds were deter-
mined when intermediate droplets between 2 clusters did
not alter the calculated concentration (Poisson 95% CI)
(20 ). Online Supplemental File 4 shows the calculations
used for determining the cffDNA fraction by use of the
dPCR results on the basis of the concentration (copies
per microliter). All statistical analysis for comparing
Streck BCTs vs EDTA tubes for both cffDNA fractions
and reference DNA concentration were performed
with Mann–Whitney U test (SigmaPlot v12.5), and
significance was accepted at P  0.05.
CONFIRMATION OF FETAL SEX AND RHD STATUS
The accuracy of dPCR and qPCR for the prenatal detec-
tion of fetal sex was ascertained at birth (Table 2). Fetal
blood group was verified after delivery through the serol-
ogy of umbilical cord blood samples.
Results
FETAL SEX DETERMINATION
For dPCR, in 100% of cases, the fetal sex predicted by
using both Y-specific targets (TSPY1 and SRY) was the
same as that determined at birth (Table 2). The Ta gra-
dient was optimized for all targets, and despite Fig. 1
illustrating equal separation at 58 °C and 56 °C, the 2D
amplitude plot illustrated better separation at 58 °C (data
not shown). In addition, at Ta 58 °C, the SRY-FAM/
Xp22.3 multiplex reaction produced a ratio closer to 1
than at Ta 56 °C (0.931 and 0.835, respectively). The
SRY assay was successful only for the male positive con-
trol by qPCR. Therefore, fetal sex was ascertained by
TSPY1 only for qPCR (Table 2; also see online Supple-
mental File 2). The results also illustrated 100% accuracy
when only the multiple-copy target gene was considered
for qPCR analysis (Table 3). Calibration curves, slopes,
y-intercepts, R2 values, and efficiencies for qPCR data are
shown in online Supplemental File 5.
Table 2. Summary of fetal sex determination and RHD genotyping results obtained from both dPCR and qPCR against results
recorded after delivery.
Platform Samples
Sex determination RHD determination
Male Female
Inconclusive
Positive Negative
InconclusiveFetus Newborn Fetus Newborn Fetus Newborn Fetus Newborn
dPCR 46
EDTA tubes 22 10 10 12 12 0 12 12 9 10 1
Streck BCTs 24 13 13 11 11 0 19 19 5 5 0
qPCR 46
EDTA tubes 22 10 10 12 12 0 0 12 22 10 0
Streck BCTs 24 13 13 11 11 0 15 19 5 5 4
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The cffDNA fraction with both Y-specific and
RHD-specific targets was calculated on the basis of the
concentration (copies per microliter) generated by dPCR
for each multiplex reaction (see online Supplemental File
4). The samples collected in Streck BCTs expressed
higher cffDNA fractions (4%–24%) and were classed as
optimal, whereas the samples collected in EDTA tubes,
during the initial stages of sample collection, illustrated
lower cffDNA fractions (0.1%–2%) and were classified
as suboptimal (Fig. 2A).
FETAL RHD GENOTYPING
By dPCR, fetal RHD genotype was correctly identified in
100% (24/24) and 95.5% (21/22) of cases for samples col-
lected in Streck BCTs and EDTA tubes, respectively (Table
3). One EDTA-collected sample (sample 12) produced a
false-positive result, since serological analysis revealed the
fetus to be RHD-negative but dPCR showed clear amplifi-
cation of the RHD7 target (18 droplets) and minimal am-
plification of the RHD5 target (3 droplets) (Fig. 3A). Fig. 3
illustrates the concentrations obtained from both target
genes (RHD5 and RHD7) and the reference gene (AGO1)
for control samples [NTC, RHD control, RHD control
(Fig. 3, A and B); samples collected in EDTA tubes (Fig.
3A); and samples collected in Streck BCTs (Fig. 3B)]. The
results show successful amplification of all 3 targets for the
RHD-positive control sample and show amplification of
only the reference AGO1 gene for the RHD-negative con-
trol sample, whereas the NTC sample showed no amplifi-
cation (Fig. 3). In addition to the false-positive result (1/46,
2%), 31 samples were correctly classified as RHD positive
(67%) and 14 samples were correctly classified asRHD neg-
ative (31%) (Fig. 3).
Optimal samples (collected in Streck BCTs), which
expressed cffDNA fractions4%, demonstrated accura-
cies of 100% and 83% on the qPCR platform for the
Table 3. Results of testing 22 and 24 maternal samples collected in EDTA tubes and Streck BCTs, respectively, with dPCR and
qPCR for fetal sex and RHD genotyping.
Platform and target gene Sensitivity, %
False-negative
results, % (n) Speciﬁcity, %
False-positive
results, % (n) Accuracy, %c
dPCR
Streck BCTsa
TSPY1 100 100 100
SRY 100 100 100
RHD5 100 100 100
RHD7 100 100 100
EDTA tubesb
TSPY1 100 100 100
SRY 100 100 100
RHD5 100 95.5 4.5 (1) 95.6
RHD7 100 95.5 4.5 (1) 95.6
qPCR
Streck BCTsa
TSPY1 100 100 100
SRY 50 54.2 (13) 100 45.8
RHD5 83.4 16.6 (4) 100 83.4
RHD7 100 100 100
EDTA tubesb
TSPY1 100 100 100
SRY 0 45.5 (10) 100 54.5
RHD5 0 59.1 (13) 100 40.9
RHD7 0 59.1 (13) 100 40.9
a cffDNA in maternal plasma 4%–24%, calculated from dPCR results.
b cffDNA in maternal plasma 0.1%–2%, calculated from dPCR results.
c Accuracy was calculated as (true positives + true negatives)/(true positives + false positives + false negatives + true negatives).
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RHD7 and RHD5 target assays, respectively. Four sam-
ples (16.6%) were classified as inconclusive because
qPCR did not detect the RHD5 target but did show
acceptable amplification of the RHD7 target (45 Cq)
(Table 3). The qPCR platform was unable to detect both
RHD-specific markers (RHD7 and RHD5) in the subop-
timal samples (2% cffDNA), despite serological and
dPCR analysis confirming that 59% (13/22) of these
EDTA-collected samples were carrying an RHD-positive
fetus.
SAMPLE COLLECTION: EDTA VS STRECK BCT
The cffDNA fractions and concentrations of reference
targets for blood collection methods with EDTA tubes
and Streck BCTs were compared by use of dPCR results.
Fig. 2A shows the mean cffDNA fraction in maternal
plasma for all 4 target regions (SRY, TSPY1, RHD5, and
RHD7) for both collection methods. The samples col-
lected in Streck BCTs showed significantly larger mean
cffDNA fractions (9%–16%) for all target regions than
those collected in EDTA (0.5%–1%) (P  0.001). The
mean cffDNA fractions generated by the EDTA-
collected samples demonstrated no significant differences
between all 4 targets (P  1). However, the cffDNA
fraction calculated on the basis of the SRY target was
significantly smaller than theTSPY1 and RHD7 cffDNA
fractions (P  0.01).
Although the concentration of each reference gene
(Xp22.3 and AGO1) (Fig. 2B) is a combination of ma-
ternal and fetal cfDNA, it is predominantly maternal in
origin (90%–95%). Samples collected in Streck BCTs
showed similar mean concentrations for Xp22.3 and
AGO1 reference genes (16.18 and 17.39 copies/L, re-
spectively; P  0.1) (Fig. 2B). The concentrations of
both reference targets (Xp22.3 and AGO1) were 40-
fold higher for maternal samples collected in EDTA
tubes compared with Streck BCTs (mean concentrations
548.04 and 869.25 copies/L, respectively), suggesting
maternal leukocyte degradation (Fig. 2B). The 2D am-
plification plots (see online Supplemental File 3) also
showed a significantly higher number of reference (HEX-
labeled) droplets formaternal samples collected in EDTA
tubes compared with maternal samples collected in
Streck BCTs (P 0.001). The fetal concentration deter-
mined from RHD5 and RHD7 amplification was similar
for samples collected in both EDTA and Streck BCTs
(P  0.1): 0.9–4.2 copies/L and 0.3–3.7 copies/L,
respectively (Fig. 3).
Discussion
Noninvasive fetal RHD genotyping by use of qPCR anal-
ysis has shown high levels of accuracy for optimal samples
(mean 97.4%) and is currently implemented in theNeth-
Fig. 2. Comparison between maternal samples collected in EDTA tubes and Streck BCTs.
(A), Mean cffDNA fraction inmaternal plasma calculated by each target gene (see online Supplemental File 1). The samples collected in Streck
BCTs show a signiﬁcantly highermean cffDNA fraction comparedwith samples collected in EDTA tubes for all 4 target regions (aP<0.001). The
cffDNA fractions on the basis of theRHD7 and TSPY1 target genes are signiﬁcantly larger than the cffDNA fraction determined by the SRY target
gene (bP < 0.01). (B), Mean concentration of reference gene regions Xp22.3 and AGO1 for maternal samples collected in EDTA tubes and
Streck BCTs. The mean concentrations of both regions were signiﬁcantly higher in EDTA tube samples than in Streck BCTs (bP<0.001). There
was no signiﬁcant difference between mean concentrations of Xp22.3 and AGO1 within each sample collection method.
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erlands and Denmark for targeted administration of pro-
phylactic anti-D (4, 10, 11, 17, 18, 25 ). In a recent
population-based cohort study, mass-throughput fetal
RHD genotyping was sufficient from the end of the first
trimester with qPCR (26 ). However, for samples taken at
11 weeks’ gestation, 16 of 865 samples (1.8%) were
incorrectly classified as RHD negative. Fetal RHD geno-
typing was also inconclusive for 393 of 4913 samples
tested (8%) (26 ). Previous studies have identified that
low cffDNA fractions can lead to false-negative results by
qPCR, limiting the sensitivity of this approach (27–29).
The oligonucleotides used in this study for RHD geno-
typing are identical to the sequences used in Finning et al.
(24 ), but for unknown reasons worked less effectively for
our qPCR assay. However, our results clearly indicate
that for suboptimal samples, the single-copy targets
(SRY, RHD5, and RHD7) were not detectable by qPCR
but achieved 100% sensitivity (95% CI) on the dPCR
platform.
Because of the gestational ages of these samples,
cffDNA is expected to be 5% (1 ). However, results
show maternal DNA degradation for EDTA-collected
samples, since the number of positive droplets for refer-
ences (Xp22.3 and AGO1) was significantly higher com-
pared with samples collected in Streck BCTs (P 0.001)
(Fig. 2B; also see online Supplemental File 3). These
novel dPCR data indicate that qPCR false-negative re-
sults were not caused by low absolute cffDNA concen-
trations, since they are similar to those expressed by op-
timal samples (Fig. 2B), but are instead a result of low
relative concentrations of cffDNA. The assay used is
highly specific, and theoretically, nonspecific amplifica-
tion should not occur, but because RHD5 and RHD7
probes have 96.5% and 100% consensus, respectively,
with the RHCE gene, it is possible that the probes are
binding to the abundant maternal RHCE, depleting
probe availability for fetal-specific RHD targets. None-
theless, when the cffDNA copy number is very low, false-
negative results are more likely, particularly for the detec-
tion of fetal single nucleotide polymorphisms for rare
mutation detection. qPCR ismore susceptible to nonspe-
cific amplification of the maternal allele, and dPCR
maybe more powerful in the detection of alleles associ-
ated with conditions such as -thalassemia and cystic
fibrosis.
The amount of fetal DNA fraction has been shown
to increase in positive correlation with time before pro-
cessing (30 ). To preserve large cffDNA fractions, it is
recommended that samples collected in EDTA tubes
should be extracted within 6 h and kept at 4 °C before
plasma extraction. Although maternal samples collected
in EDTA were processed within 6 h, all transportation of
these samples between sites was carried out at room tem-
perature for logistical reasons. The chosen references
(Xp22.3 and AGO1) were based on assumptions that
cfDNA is fragmented equally across the genome, and
dPCR analysis showed equal abundance of reference to
target loci for nonmaternal cfDNA samples, since a ratio
of approximately 1 was expressed (see online Supplemen-
tal File 3). This is important, because a previous study has
shown unequal representation of reference targets [e.g.,
TERT (telomerase reverse transcriptase) and ERV3–1
Fig. 3. Fetal RHD genotyping results frommaternal plasma samples.
The concentration (copies per microliter) (plus SD) was identiﬁed for both target regions (RHD5 and RHD7) and the reference region (AGO1).
The presence or absence of the target regions were used to determine fetal status (RHD+ or RHD−, respectively). (A), Maternal samples
collected in EDTA tubes (n = 22). (B), Maternal samples collected in Streck BCTs (n = 24). The same controls are represented in both graphs.
The control nonmaternal cfDNA RHD-positive sample (399X) exhibited ratios of 0.51 and 0.47 for RHD5/AGO1 and RHD7/AGO1, respectively.
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(endogenous retrovirus group 3, member 1)] in cfDNA
compared to genomic DNA (31 ). In addition, the
RHD control used in Fig. 3 shows a ratio of approxi-
mately 0.5, illustrating that the control sample is hemi-
zygous for the RHD gene, whereas homozygous RHD
samples tested with the same assay expressed ratios close
to 1 (data not shown).
dPCR data were used to determine the cffDNA
fraction, since they are expected to demonstrate higher
levels of sensitivity and improved accuracy for low
template copy numbers (32 ). Poisson statistics were
incorporated to determine the copy number, since
some droplets may have contained multiple targets
(33 ). The proportion of fetal target DNA was rela-
tively low [mean number of droplets 12 084, mean
number of RHD molecules 20.8 and 17.8 for samples
from EDTA tubes and Streck BCTs, respectively (data
not shown)]. However, increases in the mean number
of copies per partition for the references (e.g., AGO1),
which is shown in EDTA maternal samples [e.g., 0.62
mean copies per partition (sample 15)], result in
higher proportions of dual-positive droplets compared
to samples collected in Streck BCTs [e.g., 0.023 mean
copies per partition (sample 32)] (see online Supple-
mental File 3). Since the release of the QX100™
ddPCR system in 2012, various studies have been
conducted to find out whether its application can en-
hance or replace current qPCR-based approaches
(19, 20, 33–36). Some studies have shown equal sensi-
tivity for dPCR and qPCR, but with improved levels of
precision and day-to-day reproducibility with dPCR ap-
proaches (35, 36 ). However, several studies have shown
considerable improvements of sensitivity and specificity
on the dPCR platform compared with qPCR approaches
(19, 20, 33, 34 ). The current study also illustrates signif-
icant improvements in sensitivity for the dPCR platform,
particularly for samples expressing low relative propor-
tions of fetal DNA (2%) (Table 3).
On the basis of the qPCR data, 54% of patients
had false-negative results and in a clinical setting
would not have received required anti-D, risking allo-
immunization and subsequent HDFN. However,
dPCR results revealed no false-negative results, and
routine administration of this assay would have pre-
vented unnecessary anti-D administration in 31.1% of
patients in our study cohort. Previous studies have also
reported false-positive or inconclusive results when the
fetus expresses D-variants (4, 20, 24 ). False-positive
results do not pose a risk of alloimmunization but
result in unnecessary anti-D administration. If applied
to a clinical setting, anti-D would have been adminis-
tered to the 4 women with inconclusive results found
with qPCR for samples collected in Streck BCTs,
which in these cases was necessary since the fetuses
were RHD. On the basis of the dPCR data, only 1
woman (2%) would have received anti-D that was not
required. The oligonucleotide primers used in this
study for the RHD targets were as described by
Finning et al. (24 ). These primers should distinguish
between RHD-positive and RHD/DVI (type 1–4)
fetal genotypes by amplifying exon 7 but not exon 5
for the variant samples. However, constraints on ethics
approval prevented follow-up confirmation of the in-
conclusive result (sample 37) via analysis of fetal cord
DNA to determine the true RHD genotype of this
fetus. Both dPCR and qPCR will express similar levels
of false-positive results owing to D-variants, but our
results show that dPCR has the potential to eliminate
or reduce the occurrence of false-negative results, es-
pecially in cases in which low cffDNA fractions
(2%) are expressed.
In conclusion, this study illustrates that dPCR
shows improved accuracy for fetal sex determination
and RHD genotyping compared with qPCR, particu-
larly for suboptimal samples that express low relative
proportions of fetal DNA (2%). Despite the accu-
racy of qPCR being relatively high in most large-scale
validation studies (3, 9, 24 ), false-negative results are
still present and have been attributed to maternal
DNA degradation. Further large-scale studies are now
necessary to determine the accuracy of dPCR for fetal
RHD genotyping, but these results illustrate that
dPCR has the potential to provide a safer and more
reliable noninvasive diagnostic test for the targeted
administration of prophylaxis anti-D.
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